- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03281889
Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation
Craniospinal Irradiation Using Proton Beam Scanning With Selective Vertebral Body/Bone Sparing to Improve Marrow Reserve and Decrease Growth Decrement for Children
This research study is studying proton radiation as a possible treatment for brain tumor that requires radiation.
The radiation involved in this study is:
-Proton Radiation
Studieoversigt
Detaljeret beskrivelse
This research study is a Pilot Study to determine whether using proton therapy in participants that require craniospinal radiation (whole brain and spinal cord radiation therapy) with sparing of the bony spine will work. This is the first time investigators are examining bone sparing proton therapy in pediatric craniospinal radiation.
The FDA (the U.S. Food and Drug Administration) has not approved proton radiation for this specific disease but it has been approved for other uses.
In this research study, the investigators are studying proton radiation in participants that require craniospinal radiation. The standard of care for this procedure is photon radiation, which is very similar to proton radiation. The investigators believe that the precision of proton radiation may help to reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Shannon MacDonald, MD
- Telefonnummer: 617-643-7250
- E-mail: SMACDONALD@mgh.harvard.edu
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02214
- Rekruttering
- Massachusetts General Hospital
-
Kontakt:
- Shannon MacDonald, MD
- Telefonnummer: 617-643-7250
- E-mail: SMACDONALD@mgh.harvard.edu
-
Ledende efterforsker:
- Shannon MacDonald, MD
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Kontakt:
- Susan McGovern, MD
- E-mail: slmcgove@mdanderson.org
-
Ledende efterforsker:
- Susan McGovern, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 3 years and ≤ 18 years at the time of registration
- Histologically proven malignancy necessitating cranio-spinal irradiation. This will include patients with a diagnosis of medulloblastoma, Supratentorial primitive neuroectodermal tumor (SPNET), germ cell tumor (GCT), disseminated ependymoma, embryonal tumor with abundant neuropil and true rosettes (ETANTR), Atypical Teratoid/Rhabdoid Tumor (ATRT), and disseminated low-grade glioma (LGG).
- Life expectancy ≥ 12 months.
- Signed informed consent document and assent when appropriate.
- HGB of > 10 g/L and PLT count > 80 K/uL
Exclusion Criteria:
- Any prior therapeutic radiation therapy > 500 cGy has been delivered.
- Individuals with a history of a different malignancy are ineligible except for the following circumstances: if they have been disease-free for at least 5 years and are deemed by the investigator to be a low-risk for recurrence of that malignancy; or, have had only cervical cancer in situ, or basal cell or squamous cell carcinoma of the skin.
- Any major uncontrolled or poorly controlled intercurrent illness that would limit compliance with study requirements.
- Pregnant females are excluded. Females of childbearing age/menstruating must confirm that either they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy.
- Patients that receive concurrent chemotherapy with the exception of concurrent Vincristine.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Proton Radiotherapy
|
precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Feasibility of cranio-spinal irradiation (CSI) utilizing intensity-modulated proton therapy (IMPT) with pencil beam scanning (PBS) for vertebral body sparing (VBS) in pediatric patients.
Tidsramme: 3 months
|
IMPT using PBS delivery will be considered to be feasible as a VBS technique for CSI in pediatric patients if the rate of grade 3/4 hematologic toxicity were no more than 5% within 3 months after the completion of radiation treatment, within the range associated with conventional techniques of CSI.
Toxicity will be assess using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
|
3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Early marrow changes in the vertebral bodies
Tidsramme: 2 years
|
Summary of early marrow changes in the vertebral bodies by Magnetic resonance imaging (MRI) of the spine during radiation therapy (RT) by comparing one study MRI to the baseline pre-RT MRI.
|
2 years
|
Vertebral column growth (measured by MRI) over 5 years
Tidsramme: Annually for 5 years
|
Summary of vertebral column growth (measured by MRI) over 5 years following vertebral body sparing cranio-spinal irradiation in pediatric patients.
|
Annually for 5 years
|
Change in sitting height and standing height
Tidsramme: Annually for 5 years
|
Summary of the changes in the participants sitting and standing heights.
|
Annually for 5 years
|
Time to abnormality in spinal curvature
Tidsramme: 5 years
|
Participants are monitored both clinically and by MRI for any abnormality in spinal curvature.
The time to abnormality in spine curvature will be measured from the start of radiation to the date of documented abnormality or censored at the date of last follow-up for patients still alive with normal spine.
|
5 years
|
Disease Free Survival
Tidsramme: 5 years
|
Disease-free survival is measured from the start of radiation to the date of progressive disease based on imaging studies obtained as standard care or to the date of death due to any cause, whichever is earlier.
Disease-free survival will be estimated using the Kaplan-Meier method.
Patients without progressive disease and still alive will be censored at their date of last contact.
|
5 years
|
Pattern of Disease Relapse
Tidsramme: 2 years
|
Summary of the sites where the cancer relapses.
Relapse is the regrowth of cancer cells.
|
2 years
|
Complete blood counts (CBC) over time
Tidsramme: Annually for 5 years
|
Summary of the change in complete blood counts (CBC) over time as determined by yearly blood samples.
|
Annually for 5 years
|
Change in levels of vitamin D, calcium, and growth hormones over time
Tidsramme: Annually for 5 years
|
Summary of the changes in blood levels of vitamin D, calcium, and growth hormones.
|
Annually for 5 years
|
Weight
Tidsramme: Annually for 5 years
|
Summary of the changes in weight of the participants as assessed by yearly evaluations.
|
Annually for 5 years
|
BMI
Tidsramme: Annually for 5 years
|
Summary of the body mass index (BMI) of the participants as assessed by yearly physical evaluations.
|
Annually for 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Shannon MacDonald, MD, Massachusetts General Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 17-283
- U19CA021239-37 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hjerne svulst
-
Assistance Publique Hopitaux De MarseilleUkendt
-
National Institute of Mental Health (NIMH)AfsluttetKÆLEDYR | Brain Imaging | Cannabinoid | CB1Forenede Stater
-
GE HealthcareAfsluttetBrain Imaging | Billedbehandling af hele kroppenForenede Stater
-
Mayo ClinicTilmelding efter invitationBrain Imaging | Billedbehandling af hele kroppenForenede Stater
-
Tang-Du HospitalIkke rekrutterer endnuPsykisk lidelse | Sociale medier | Brain Imaging
-
University Hospital TuebingenAfsluttetFunktionel dyspepsi | Mad | Brain ImagingTyskland
-
University of MichiganAfsluttetÆndringer i Brain Network ConnectivityForenede Stater
-
School of Health Sciences GenevaUniversity of Lausanne Hospitals; University of Geneva, SwitzerlandRekrutteringMR scanning | Opførsel | Funktionel magnetisk resonansbilleddannelse | Musik | Udvikling, barn | Brain Imaging | Executive funktioner | Hjerneplasticitet | Interventioner | Kunst | Strukturel hjerneforbindelseSchweiz
-
Rigshospitalet, DenmarkLundbeck Foundation; Filadelfia Epilepsy Hospital; Lennart Grams Mindefond...AfsluttetKirurgi | Refraktær epilepsi | Elektroencefalografi | Brain ImagingDanmark
-
Sándor BeniczkyHospital del Mar; Centro Hospitalar e Universitário de Coimbra, E.P.E.; Motol... og andre samarbejdspartnereAktiv, ikke rekrutterendeKirurgi | Refraktær epilepsi | Elektroencefalografi | Brain ImagingSpanien, Portugal, Østrig, Tjekkiet, Danmark, Tyskland, Italien, Rumænien
Kliniske forsøg med Proton Beam
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RekrutteringMelanom | SarkomForenede Stater
-
The New York Proton CenterRekrutteringProstatakræftForenede Stater
-
Thompson Cancer Survival CenterRekrutteringBrystkræft | Brystkræft fase I | Brystkræft fase II | Brystkræft fase IIIForenede Stater
-
Abramson Cancer Center at Penn MedicineRekrutteringLivmoderhalskræft | LivmoderkræftForenede Stater
-
University of Maryland, BaltimoreAfsluttetHoved- og halskræft | Orofarynx pladecellekarcinom | Oropharynx CancerForenede Stater
-
The New York Proton CenterRekrutteringBrystkræft | Hoved- og halskræft | Gynækologisk kræft | Prostatakræft | Thoraxkræft | CNS kræft | GI-kræftForenede Stater
-
Washington University School of MedicineRekrutteringTilbagevendende endetarmskræftForenede Stater
-
Oregon Aesthetic TechnologiesAfsluttet
-
Temple UniversityAllerganUkendtKritisk sygdom | Bakterielle infektioner | NyresvigtForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Afsluttet